CannabisNewsBreaks

TuesdayApr 19, 2022 3:00 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has begun its multi-week human clinical hypertension study. The randomized, double blinded, placebo-controlled, cross-over study in 60 people, HYPER-H21-4, is the most comprehensive study ever undertaken by Lexaria. HYPER-H21-4 is designed to enhance Lexaria’s probability of success with its expected subsequent Investigational New Drug (“IND”) application filing to seek U.S. Food and Drug Administration (“FDA”) approval to commence registered clinical testing at phase I level or higher, to be determined in consultation with the FDA. The human study is also expected to enhance Lexaria’s…

Continue Reading

TuesdayApr 19, 2022 12:36 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Upcoming Conferences

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, will be involved in several conferences in April and May. Company management will be participating at the Benzinga Spring Cannabis Capital Conference, scheduled for April 20–21, 2022, in Miami Beach, Florida. InMed executives will be meeting virtually with institutions and industry representatives. Company executives will also be at Canaccord Genuity’s sixth annual Global Cannabis Conference held on May 11, 2022. A recording of the company’s presentation will be available on InMed’s investor relations website following the event. Company leaders will also be available for…

Continue Reading

MondayApr 18, 2022 2:38 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expanding Rare Cannabinoid Manufacturing Scale

InMed Pharmaceuticals (NASDAQ: INM), a rare cannabinoid drug developer, is expanding its product manufacturing scale, thanks largely to the acquisition of consumer-focused rare cannabinoids manufacturer BayMedica last year. “InMed’s most-recent Q2 financial statement reported revenues of $0.3 million from commercial sales of cannabichromene (‘CBC’) to the health and wellness market following the BayMedica acquisition. Since January, the company has also been selling cannabicitran (‘CBT’) to the health and wellness market on a B2B basis,” a recent article reads. “The company’s forward-looking focus on bringing new cannabinoid products to commercial scale anticipates scales of cannabidivarin (‘CBDV’) and tetrahydrocannabivarin (‘THCV’) in the…

Continue Reading

MondayApr 18, 2022 1:34 pm

CannabisNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) on ‘Solid Ground in 2022 and Beyond’

Red White & Bloom (CSE: RWB) (OTCQX: RWBYF), a company positioning itself to be one of the top three multistate operators in the United States in cannabis and hemp-derived product lines, has adopted a strategy anchored in operating a house of brands as it anticipates the commoditization of the cannabis market. “This is going to be a commoditized market, and our strategy is such that we are going to stand on our brands going forward. We just need to fortify what we are doing in the markets that we are in right now,” a recent article quotes RWB CEO Brad…

Continue Reading

ThursdayApr 14, 2022 12:54 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Results from Pulmonary Hypertension Clinical Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released data from its HYPER-H21-3 human study. The company noted that data from its simulated pulmonary hypertension clinical study indicate positive safety and efficacy findings. Specifically, results show a tendency (p=0.1) during 15 minutes of simulated low levels of oxygen (hypoxia) for reduced pulmonary artery systolic pressure (“PASP”) with DehydraTECH-CBD treatment versus placebo. According to the announcement, PASP was significantly attenuated by about 5 mmHg or 41% overall (p=0.045) in male participants, which could indicate potential differences by sex in responsiveness to CBD treatment under hypoxic stress conditions. The…

Continue Reading

TuesdayApr 12, 2022 1:05 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer. According to the announcement, NIC-H22-1 is a minimum 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study to compare Lexaria's DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the U.S. such as ON! and Zyn. Lexaria hopes to evidence that processing purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences compared to brands currently on the market. The study’s primary objective is data collection…

Continue Reading

TuesdayApr 12, 2022 12:49 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) to Participate in Leading Cannabis Event

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has announced that CEO Luis Merchan will be presenting at the upcoming Benzinga Cannabis Capital Conference. The event is scheduled for April 20–21, 2022, in Miami, Florida. Merchan’s presentation is slated to begin at 3:20 p.m. ET on April 20. In addition to Merchan’s presentation, members of Flora's management team will be scheduling one-on-one investor meetings throughout the day. The Benzinga Cannabis Capital Conference gathers together more than 1,000 of the top movers and shakers in the cannabis industry and offers an invaluable opportunity for…

Continue Reading

MondayApr 11, 2022 3:13 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Taking Diverse Product Portfolio to New Markets

Flora Growth Corp. (NASDAQ: FLGC) recently announced the successful import of Mambe CBD-containing food and beverage products into the United States from Colombia. The move capitalized on a new law signed by Colombian President Ivan Duque, which provides the necessary regulatory framework for cannabis product use and export. “Our team anticipated this regulatory update and has been laying the necessary foundation to expand this new supply chain pathway allowing Flora to quickly bring our diverse product portfolio and low-cost cannabis inputs to new high-growth international markets,” a recent article quotes Flora Growth CEO Luis Merchan as saying. Flora Growth also…

Continue Reading

FridayApr 08, 2022 2:36 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Hopes to Demonstrate DehydraTECH’s Superior Performance in Ongoing Epilepsy Research Program

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced the beginning of the first phase of its epilepsy research program, EPIL-A21-1. “The research program will assess the seizure-inhibiting activity of cannabidiol (‘CBD’) administered via the company’s proprietary DehydraTECH(TM) technology, compared to the only FDA-approved CBD-based seizure medication…. The EPIL-A21-1 research program contains two main studies to be performed in rodents following the first phase – a pilot animal model that has already begun. The main studies are slated to commence in May/June and involve an acute seizure model induced by electrical stimulation and chemically induced seizure models,” a recent article reads. “Using…

Continue Reading

FridayApr 08, 2022 2:04 pm

CannabisNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Gaining Momentum, Fortifying Vertically Integrated Businesses

Red White & Bloom (CSE: RWB) (OTCQX: RWBYF) has so far set base in Michigan, Florida, California, and Illinois, in what marks an aggressive and successful expansion plan. “For the balance of 2021 and throughout 2022, the company will focus on the continued growth of our top-line revenue and bottom-line results through expansion of our house of brands that continue to gain momentum, fortification of our vertically integrated businesses, and the synergies from our M&A success,” a recent article quotes Brad Rogers, the chairman and CEO of the company, as saying. RWB recently announced the acquisition of PharmaCo. “The purchase…

Continue Reading